Felix A Ratjen

List of Publications by Year
in descending order

343 papers	21,380 citations	14655 66 h-index	11939 134 g-index
357 all docs	357 docs citations	357 times ranked	13286 citing authors

#	Article	IF	Citations
1	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	27.0	1,920
2	Lumacaftorâ€"Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
3	Cystic fibrosis. Lancet, The, 2003, 361, 681-689.	13.7	936
4	Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2006, 57, 306-311.	3.0	715
5	Consensus statement for inert gas washout measurement using multiple- and single- breath tests. European Respiratory Journal, 2013, 41, 507-522.	6.7	631
6	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	10.7	573
7	ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis, 2018, 17, 153-178.	0.7	521
8	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 2014, 13, S23-S42.	0.7	438
9	Cystic fibrosis. Nature Reviews Disease Primers, 2015, 1, 15010.	30.5	403
10	Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nature Biotechnology, 2012, 30, 876-882.	17.5	371
11	Exhaled Nitric Oxide in Pulmonary Diseases. Chest, 2010, 138, 682-692.	0.8	347
12	The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Patients With Cystic Fibrosis. Chest, 2010, 137, 171-176.	0.8	329
13	Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With <emph type="ital">Pseudomonas aeruginosa</emph><subtitle>A Randomized Controlled Trial</subtitle>. JAMA - Journal of the American Medical Association, 2010, 303, 1707.	7.4	291
14	Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax, 2010, 65, 286-291.	5.6	253
15	Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Annals of Internal Medicine, 2020, 173, 989-1001.	3.9	244
16	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6â€"11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	10.7	243
17	Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Human Genetics, 1997, 100, 365-377.	3.8	242
18	Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet, The, 2001, 358, 983-984.	13.7	211

#	Article	IF	Citations
19	Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respiratory Medicine,the, 2018, 6, 545-553.	10.7	205
20	Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D- CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respiratory Medicine,the, 2013, 1, 630-638.	10.7	203
21	Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. European Respiratory Journal, 2012, 40, 61-66.	6.7	201
22	Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax, 2010, 65, 379-383.	5.6	199
23	Cystic Fibrosis Foundation Pulmonary Guideline. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection. Annals of the American Thoracic Society, 2014, 11, 1640-1650.	3.2	197
24	Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respiratory Medicine,the, 2014, 2, 902-910.	10.7	191
25	Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment ofPseudomonas aeruginosa colonization in cystic fibrosis. , 1998, 25, 88-92.		178
26	Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 307, 2269-77.	7.4	175
27	Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections. Annals of the American Thoracic Society, 2014, 11, 1120-1129.	3.2	175
28	Stenotrophomonas maltophilia in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 635-640.	5.6	156
29	Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 719-725.	5.6	154
30	Lung Clearance Index as an Outcome Measure for Clinical Trials in Young Children with Cystic Fibrosis. A Pilot Study Using Inhaled Hypertonic Saline. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 456-460.	5.6	147
31	Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 529-539.	5.6	147
32	Lumacaftor/Ivacaftor in Patients Aged 6â€“11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 912-920.	5.6	138
33	Cystic Fibrosis: Pathogenesis and Future Treatment Strategies. Respiratory Care, 2009, 54, 595-605.	1.6	138
34	Mucolytics in cystic fibrosis. Paediatric Respiratory Reviews, 2007, 8, 24-29.	1.8	130
35	Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1216-1225.	5.6	127
36	Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. Journal of Cystic Fibrosis, 2013, 12, 482-486.	0.7	117

#	Article	IF	Citations
37	Inhalation of Moli1901 in Patients With Cystic Fibrosis. Chest, 2007, 131, 1461-1466.	0.8	116
38	Influence of Interleukinâ€10 onAspergillus fumigatusInfection in Patients with Cystic Fibrosis. Journal of Infectious Diseases, 2005, 191, 1988-1991.	4.0	115
39	Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. European Respiratory Journal, 2014, 43, 817-823.	6.7	115
40	Effect of Azithromycin on Systemic Markers of Inflammation in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa. Chest, 2012, 142, 1259-1266.	0.8	110
41	Airway Nitric Oxide Levels in Cystic Fibrosis Patients Are Related to a Polymorphism in the Neuronal Nitric Oxide Synthase Gene. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 2172-2176.	5.6	109
42	Increased Arginase Activity in Cystic Fibrosis Airways. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1523-1528.	5.6	109
43	Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 987-995.	5.6	108
44	Inconclusive Diagnosis of Cystic Fibrosis After Newborn Screening. Pediatrics, 2015, 135, e1377-e1385.	2.1	105
45	Improvement of Alveolar Glutathione and Lung Function but Not Oxidative State in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 822-828.	5.6	104
46	Alveolar inflammation in cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 217-227.	0.7	103
47	Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. Journal of Pediatrics, 1999, 135, 770-772.	1.8	97
48	Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Annals of the American Thoracic Society, 2015, 12, 932-939.	3.2	96
49	<scp>O</scp>rkambiÂ® and amplifier coâ€therapy improves function from a rare <scp>CFTR</scp> mutation in geneâ€edited cells and patient tissue. EMBO Molecular Medicine, 2017, 9, 1224-1243.	6.9	94
50	Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 197, e1-e19.	5.6	92
51	Nitrogen Redox Balance in the Cystic Fibrosis Airway. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 387-390.	5.6	89
52	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 802-809.	10.7	89
53	Multiple Breath Nitrogen Washout: A Feasible Alternative to Mass Spectrometry. PLoS ONE, 2013, 8, e56868.	2.5	87
54	Exercise and physical activity in children with cystic fibrosis. Paediatric Respiratory Reviews, 2009, 10, 105-109.	1.8	86

#	Article	IF	Citations
55	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 539-549.	0.7	85
56	Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax, 2013, 68, 746-751.	5.6	81
57	Cystic fibrosis gene modifierSLC26A9modulates airway response to CFTR-directed therapeutics. Human Molecular Genetics, 2016, 25, ddw290.	2.9	81
58	Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: A review. Journal of Cystic Fibrosis, 2009, 8, 361-369.	0.7	80
59	Early lung disease in cystic fibrosis. Lancet Respiratory Medicine,the, 2013, 1, 148-157.	10.7	80
60	Normative data for multiple breath washout outcomes in school-aged Caucasian children. European Respiratory Journal, 2020, 55, 1901302.	6.7	79
61	Inhaledl-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 208-212.	5.6	76
62	Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous Mycobacteria, Anaerobic Bacteria, and Fungi. Annals of the American Thoracic Society, 2014, 11, 1298-1306.	3.2	75
63	Pulmonary Surfactant, Lung Function, and Endobronchial Inflammation in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1000-1005.	5.6	73
64	Treatment of Aspergillus fumigatus in Patients with Cystic Fibrosis: A Randomized, Placebo-Controlled Pilot Study. PLoS ONE, 2012, 7, e36077.	2.5	72
65	Restoring Airway Surface Liquid in Cystic Fibrosis. New England Journal of Medicine, 2006, 354, 291-293.	27.0	70
66	Diagnostic value of serum antibodies in earlyPseudomonas aeruginosa infection in cystic fibrosis patients. Pediatric Pulmonology, 2007, 42, 249-255.	2.0	69
67	Physiologic endpoints for clinical studies for cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 416-423.	0.7	69
68	Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 8-13.	0.7	68
69	Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia. European Respiratory Journal, 2016, 47, 829-836.	6.7	66
70	Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia. Npj Genomic Medicine, 2017, 2, 12.	3.8	66
71	Skeletal Muscle Metabolism in Cystic Fibrosis and Primary Ciliary Dyskinesia. Pediatric Research, 2011, 69, 40-45.	2.3	64
72	beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics and Genomics, 2002, 12, 347-353.	5.7	62

#	Article	IF	Citations
73	Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 78-83.	0.7	62
74	Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 755-762.	0.7	62
75	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	5.8	62
76	Pulmonary Exacerbations in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2015, 12, S200-S206.	3.2	62
77	Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. European Respiratory Journal, 2015, 46, 1055-1064.	6.7	61
78	Inter-test reproducibility of the lung clearance index measured by multiple breath washout. European Respiratory Journal, 2017, 50, 1700433.	6.7	61
79	Diagnostic Value of Nasal Nitric Oxide Measured with Non-Velum Closure Techniques for Children with Primary Ciliary Dyskinesia. Journal of Pediatrics, 2011, 159, 420-424.	1.8	60
80	Endothelial Nitric Oxide Synthase Variants in Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 390-394.	5.6	59
81	Hemorrhage Rates From Brain Arteriovenous Malformation in Patients With Hereditary Hemorrhagic Telangiectasia. Stroke, 2015, 46, 1362-1364.	2.0	58
82	Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax, 2017, 72, 327-332.	5.6	58
83	Correlation of Lung Clearance Index with Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Subjects with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1073-1075.	5.6	57
84	Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. The Cochrane Library, 2013, , CD007168.	2.8	55
85	Hyperpolarised¹²⁹Xe magnetic resonance imaging to monitor treatment response in children with cystic fibrosis. European Respiratory Journal, 2019, 53, 1802188.	6.7	55
86	Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. Respiratory Research, 2006, 7, 87.	3.6	54
87	Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 395-400.	0.7	53
88	Asymmetric Dimethylarginine Contributes to Airway Nitric Oxide Deficiency in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1363-1368.	5.6	51
89	A Systematic Approach to Multiple Breath Nitrogen Washout Test Quality. PLoS ONE, 2016, 11, e0157523.	2.5	51
90	Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 471-476.	2.0	50

#	Article	IF	Citations
91	Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis. Thorax, 2018, 73, 451-458.	5.6	50
92	The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF. Journal of Cystic Fibrosis, 2019, 18, 35-43.	0.7	50
93	Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1361-1369.	5.6	50
94	Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?. European Respiratory Journal, 2013, 42, 527-538.	6.7	49
95	The cystic fibrosis gender gap: Potential roles of estrogen. Pediatric Pulmonology, 2014, 49, 309-317.	2.0	49
96	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Metabolic and Respiratory Effects of Growth Hormone in Children With Cystic Fibrosis. Pediatrics, 2007, 119, e1230-e1238.	2.1	48
97	Reliability and validity of the habitual activity estimation scale (HAES) in patients with cystic fibrosis. Pediatric Pulmonology, 2008, 43, 345-353.	2.0	47
98	Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis. Current Pharmaceutical Design, 2012, 18, 726-736.	1.9	47
99	Does earlier lobectomy result in better long-term pulmonary function in children with congenital lung anomalies?. Journal of Pediatric Surgery, 2012, 47, 852-856.	1.6	47
100	Pulmonary function after early vs late lobectomy during childhood: a preliminary study. Journal of Pediatric Surgery, 2009, 44, 893-895.	1.6	46
101	Effects of Sex and of Gene Variants in Constitutive Nitric Oxide Synthases on Exhaled Nitric Oxide. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1113-1116.	5.6	45
102	Multidrugâ€"resistant organisms in cystic fibrosis: management and infectionâ€"control issues. Expert Review of Anti-Infective Therapy, 2006, 4, 807-819.	4.4	45
103	Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 262-266.	0.7	45
104	Cystic fibrosis lung disease: The role of nitric oxide. Pediatric Pulmonology, 1999, 28, 442-448.	2.0	44
105	Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine, 2006, 12, 428-432.	2.6	44
106	Sputum Induction in Routine Clinical Care of Children with Cystic Fibrosis. Journal of Pediatrics, 2010, 157, 1006-1011.e1.	1.8	43
107	Hyperpolarized Gas Magnetic Resonance Imaging of Pediatric Cystic Fibrosis Lung Disease. Academic Radiology, 2019, 26, 344-354.	2.5	43
108	L-Ornithine Derived Polyamines in Cystic Fibrosis Airways. PLoS ONE, 2012, 7, e46618.	2.5	43

#	Article	IF	Citations
109	Cystic Fibrosis: Detecting Changes in Airway Inflammation with FDG PET/CT. Radiology, 2012, 264, 868-875.	7.3	42
110	Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 1224-1232.	2.0	41
111	Inhaled liposomal amikacin. Expert Review of Respiratory Medicine, 2014, 8, 401-409.	2.5	41
112	Openâ€label, followâ€on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology, 2012, 47, 641-648.	2.0	40
113	Integrating the multiple breath washout test into international multicentre trials. Journal of Cystic Fibrosis, 2020, 19, 602-607.	0.7	40
114	PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. Journal of Cystic Fibrosis, 2021, 20, 205-212.	0.7	39
115	Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: A pilot project. Pediatric Pulmonology, 2008, 43, 753-759.	2.0	38
116	Effect of Endoscopic Sinus Surgery on Pulmonary Function and Microbial Pathogens in a Pediatric Population With Cystic Fibrosis. JAMA Otolaryngology, 2011, 137, 542.	1.2	38
117	A two-center analysis of hyperpolarized 129Xe lung MRI in stable pediatric cystic fibrosis: Potential as a biomarker for multi-site trials. Journal of Cystic Fibrosis, 2019, 18, 728-733.	0.7	38
118	Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Annals of the American Thoracic Society, 2021, 18, 1397-1405.	3.2	38
119	Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. , 2009, , CD007168.		36
120	Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Annals of the American Thoracic Society, 2015, 12, 1398-1406.	3.2	36
121	Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2015, 14, 770-776.	0.7	36
122	Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 1412-1418.	3.2	35
123	Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis. Journal of Cystic Fibrosis, 2021, 20, 243-249.	0.7	35
124	Recent advances in cystic fibrosis. Paediatric Respiratory Reviews, 2008, 9, 144-148.	1.8	34
125	The Approach toPseudomonas aeruginosain Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 587-595.	2.1	34
126	Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. Journal of Cystic Fibrosis, 2013, 12, 575-583.	0.7	34

#	Article	IF	Citations
127	Novel outcome measures for clinical trials in cystic fibrosis. Pediatric Pulmonology, 2015, 50, 302-315.	2.0	34
128	Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis. Journal of Pediatrics, 2017, 184, 165-171.e1.	1.8	34
129	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. The Cochrane Library, 2017, 10, CD009528.	2.8	34
130	Eradication of early P. aeruginosa infection in children <7â€¯years of age with cystic fibrosis: The early study. Journal of Cystic Fibrosis, 2019, 18, 78-85.	0.7	34
131	Lung Clearance Index to Track Acute Respiratory Events in School-Age Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 977-986.	5.6	34
132	A Comparison of Amount and Speed of Deposition Between the PARI LC STAR^{Â®} Jet Nebulizer and an Investigational eFlow^{Â®} Nebulizer. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2011, 24, 157-163.	1.4	33
133	Comparison of Functional Free-Breathing Pulmonary 1H and Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Cystic Fibrosis. Academic Radiology, 2021, 28, e209-e218.	2.5	33
134	Update in Cystic Fibrosis 2012. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 915-919.	5.6	32
135	Alternative outcomes for the multiple breath washout in children with CF. Journal of Cystic Fibrosis, 2015, 14, 490-496.	0.7	32
136	Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 727-732.	0.7	32
137	Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 526-528.	5.6	32
138	Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial. Annals of the American Thoracic Society, 2021, 18, 75-83.	3.2	32
139	CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis. A Cross-Sectional Study. Annals of the American Thoracic Society, 2018, 15, 209-216.	3.2	32
140	Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. Respiratory Research, 2005, 6, 133.	3.6	31
141	Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 172-178.	0.7	31
142	Airway nitric oxide in infants with acute wheezy bronchitis. Pediatric Allergy and Immunology, 2000, 11, 230-235.	2.6	30
143	Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study. Journal of Cystic Fibrosis, 2020, 19, 931-933.	0.7	30
144	Emerging therapies for cystic fibrosis lung disease. Expert Opinion on Emerging Drugs, 2010, 15, 653-659.	2.4	29

#	Article	IF	Citations
145	A randomized controlled trial to evaluate the lung clearance index as an outcome measure for early phase studies in patients with cystic fibrosis. Respiratory Medicine, 2016, 112, 59-64.	2.9	29
146	Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: shortâ€term tolerability, adherence, and safety. Pediatric Pulmonology, 2011, 46, 666-671.	2.0	28
147	Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis. Pediatrics, 2016, 138, .	2.1	28
148	Long-term safety of lumacaftorâ€“ivacaftor in children aged 2â€“5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respiratory Medicine,the, 2021, 9, 977-988.	10.7	28
149	Single-Lung Transplantation in a Patient With Cystic Fibrosis and an Asymmetric Thorax. Annals of Thoracic Surgery, 1997, 64, 1456-1458.	1.3	27
150	CIPROFLOXACIN-INDUCED ACUTE RENAL FAILURE IN A PATIENT WITH CYSTIC FIBROSIS. Pediatric Infectious Disease Journal, 2001, 20, 320-321.	2.0	27
151	Diagnosing and managing infection in CF. Paediatric Respiratory Reviews, 2006, 7, S151-S153.	1.8	26
152	New pulmonary therapies for cystic fibrosis. Current Opinion in Pulmonary Medicine, 2007, 13, 541-546.	2.6	26
153	Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis. Pediatric Pulmonology, 2009, 44, 939-940.	2.0	26
154	Utility of Contrast Echocardiography for Pulmonary Arteriovenous Malformation Screening in Pediatric Hereditary Hemorrhagic Telangiectasia. Journal of Pediatrics, 2012, 160, 1039-1043.e1.	1.8	26
155	What's new in CF airway inflammation: An update. Paediatric Respiratory Reviews, 2006, 7, S70-S72.	1.8	25
156	Effect of equipment dead space on multiple breath washout measures. Respirology, 2015, 20, 459-466.	2.3	25
157	Long-term safety and efficacy of lumacaftorâ€“ivacaftor therapy in children aged 6â€“11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Lancet Respiratory Medicine,the, 2021, 9, 721-732.	10.7	25
158	P2Y2 receptor polymorphisms and haplotypes in cystic fibrosis and their impact on Ca2+ influx. Pharmacogenetics and Genomics, 2006, 16, 199-205.	1.5	24
159	Nasal Staphylococcus aureus Carriage Is Not a Risk Factor for Lower-Airway Infection in Young Cystic Fibrosis Patients. Journal of Clinical Microbiology, 2007, 45, 2979-2984.	3.9	24
160	Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis, 2014, 13, 74-79.	0.7	24
161	False-Positive Newborn Screening for Cystic Fibrosis and Health Care Use. Pediatrics, 2017, 140, .	2.1	24
162	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24

#	Article	IF	Citations
163	Building global development strategies for cf therapeutics during a transitional cftr modulator era. Journal of Cystic Fibrosis, 2020, 19, 677-687.	0.7	24
164	Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax, 2021, 76, 1255-1265.	5.6	24
165	Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis. European Respiratory Journal, 2021, 58, 2003380.	6.7	24
166	The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatric Pulmonology, 2011, 46, 554-558.	2.0	23
167	Brain Arteriovenous Malformations in Patients With Hereditary Hemorrhagic Telangiectasia: Clinical Presentation and Anatomical Distribution. Pediatric Neurology, 2013, 49, 445-450.	2.1	23
168	Emerging drugs for cystic fibrosis. Expert Opinion on Emerging Drugs, 2014, 19, 143-155.	2.4	23
169	Initial evaluation of the Parent Cystic Fibrosis Questionnaireâ€"Revised (CFQ-R) in infants and young children. Journal of Cystic Fibrosis, 2015, 14, 403-411.	0.7	23
170	Correcting for tissue nitrogen excretion in multiple breath washout measurements. PLoS ONE, 2017, 12, e0185553.	2.5	23
171	Microaspiration in Infants with Laryngomalacia. Laryngoscope, 2004, 114, 1592-1596.	2.0	22
172	Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. Journal of Cystic Fibrosis, 2012, 11, 63-67.	0.7	22
173	Aquagenic Wrinkling of the Palms in a Patient with Cystic Fibrosis. New England Journal of Medicine, 2013, 369, 2362-2363.	27.0	22
174	The lung clearance index as a monitoring tool in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2018, 24, 579-585.	2.6	22
175	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. The Cochrane Library, 2020, 6, CD010004.	2.8	22
176	A Pilot Study to Compare Tobramycin 80 mg Injectable Preparation wth 300 mg Solution for Inhalation in Cystic Fibrosis Patients. Canadian Respiratory Journal, 2008, 15, 259-262.	1.6	21
177	Symptomatic Liver Involvement in Neonatal Hereditary Hemorrhagic Telangiectasia. Pediatrics, 2011, 127, e1615-e1620.	2.1	21
178	New Therapies in Cystic Fibrosis. Current Pharmaceutical Design, 2012, 18, 614-627.	1.9	21
179	Outcomes of Cystic Fibrosis Screeningâ€"Positive Infants With Inconclusive Diagnosis at School Age. Pediatrics, 2021, 148, .	2.1	21
180	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. , 2012, 11, CD009528.		20

#	Article	IF	Citations
181	Newborn screening for cystic fibrosis. Expert Review of Respiratory Medicine, 2015, 9, 619-631.	2.5	20
182	Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations. European Respiratory Journal, 2017, 50, 1700244.	6.7	20
183	Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis. BMC Pediatrics, 2019, 19, 369.	1.7	20
184	The effect of inhaled hypertonic saline on lung structure in children aged 3â€“6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 669-678.	10.7	20
185	Comparison of throat swabs and nasopharyngeal suction specimens in non-sputum-producing patients with cystic fibrosis. Pediatric Pulmonology, 2006, 41, 839-843.	2.0	19
186	Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2007, 59, 1135-1140.	3.0	19
187	The Diagnostic Yield of Rescreening for Arteriovenous Malformations in Children with Hereditary Hemorrhagic Telangiectasia. Journal of Pediatrics, 2014, 165, 197-199.	1.8	19
188	Pulmonary exacerbations and parentâ€reported outcomes in children <6 years with cystic fibrosis. Pediatric Pulmonology, 2015, 50, 236-243.	2.0	19
189	Clinical Outcomes Associated with Burkholderia cepacia Complex Infection in Patients with Cystic Fibrosis. Annals of the American Thoracic Society, 2020, 17, 1542-1548.	3.2	19
190	Effect of Arginase Inhibition on Pulmonary L-Arginine Metabolism in Murine Pseudomonas Pneumonia. PLoS ONE, 2014, 9, e90232.	2.5	19
191	A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients. Stem Cell Reports, 2021, 16, 2825-2837.	4.8	19
192	Epidemiology of borderline oxacillinâ€resistant Staphylococcus aureus in Pediatric cystic fibrosis. Pediatric Pulmonology, 2011, 46, 489-496.	2.0	18
193	Antiâ€inflammatories and mucociliary clearance therapies in the age of CFTR modulators. Pediatric Pulmonology, 2019, 54, S46-S55.	2.0	18
194	A theory for polymicrogyria and brain arteriovenous malformations in HHT. Neurology, 2019, 92, 34-42.	1.1	18
195	Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema. JAMA Pediatrics, 2020, 174, 332.	6.2	18
196	Prevalence of Pulmonary Arteriovenous Malformations in Children versus Adults with Hereditary Hemorrhagic Telangiectasia. Journal of Pediatrics, 2013, 163, 282-284.	1.8	17
197	Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials. Journal of Cystic Fibrosis, 2022, 21, e204-e207.	0.7	17
198	Cystic fibrosisâ€“related diabetes onset can be predicted using biomarkers measured at birth. Genetics in Medicine, 2021, 23, 927-933.	2.4	17

#	Article	IF	Citations
199	Update in Cystic Fibrosis 2008. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 445-448.	5.6	16
200	Is There a Role for Antimicrobial Stewardship in Cystic Fibrosis?. Annals of the American Thoracic Society, 2014, 11, 1116-1119.	3.2	16
201	Genetic Diversity among Isolates of Aspergillus fumigatus in Patients with Cystic Fibrosis. Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology, 1997, 285, 450-455.	0.5	15
202	Serum galactomannan in cystic fibrosis patients colonized withAspergillusspecies. Medical Mycology, 2012, 50, 658-660.	0.7	15
203	Physiological correlates of pulmonary function in children with cystic fibrosis. Pediatric Pulmonology, 2014, 49, 878-884.	2.0	15
204	Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 542-549.	0.7	15
205	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. The Cochrane Library, 2017, 6, CD006961.	2.8	15
206	Incidence and risk factors of paediatric cystic fibrosis-related diabetes. Journal of Cystic Fibrosis, 2019, 18, 874-878.	0.7	15
207	Normative multiple-breath washout data in school-aged children corrected for sensor error. European Respiratory Journal, 2022, 60, 2102398.	6.7	15
208	Lavage lipidomics signatures in children with cystic fibrosis and protracted bacterial bronchitis. Journal of Cystic Fibrosis, 2019, 18, 790-795.	0.7	14
209	Reduced Lung Function in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 2-3.	5.6	13
210	Cystic Fibrosis: The Role of the Small Airways. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2012, 25, 261-264.	1.4	13
211	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. , 2015, , CD009528.		13
212	Lung clearance index response in patients with CF with class III CFTR mutations. Thorax, 2016, 71, 476-477.	5.6	13
213	Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 386-391.	0.7	13
214	Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial. Trials, 2017, 18, 293.	1.6	13
215	Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients. Journal of Cystic Fibrosis, 2017, 16, 58-63.	0.7	13
216	Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population. Annals of the American Thoracic Society, 2018, 15, 827-836.	3.2	13

#	Article	IF	Citations
217	Free-breathing MRI for monitoring ventilation changes following antibiotic treatment of pulmonary exacerbations in paediatric cystic fibrosis. European Respiratory Journal, 2021, 57, 2003104.	6.7	13
218	Tuberculoma of the pons. Pediatric Neurology, 1999, 20, 57-59.	2.1	12
219	Exhaled Nitric Oxide in Children after Accidental Exposure to Chlorine Gas. Inhalation Toxicology, 2007, 19, 895-898.	1.6	12
220	Juvenile Polyposis Syndrome, SMAD4 Mutations, and Hereditary Hemorrhagic Telangiectasia. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 120-122.	1.8	12
221	Tiotropium RespimatÂ® in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis, 2015, 14, 608-614.	0.7	12
222	Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment. Journal of Cystic Fibrosis, 2018, 17, 723-728.	0.7	12
223	Lung clearance index is elevated in young children with symptomâ€controlled asthma. Health Science Reports, 2018, 1, e58.	1.5	12
224	Proteomic Profiling to Identify Blood Biomarkers Predictive of Response to Azithromycin in Children and Adolescents With Cystic Fibrosis. Chest, 2019, 156, 667-673.	0.8	12
225	Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2019, 16, 861-867.	3.2	12
226	Assessing the feasibility of hyperpolarized ¹²⁹Xe multipleâ€breath washout MRI in pediatric cystic fibrosis. Magnetic Resonance in Medicine, 2020, 84, 304-311.	3.0	12
227	Genotypeâ€"Phenotype Correlations in Children with HHT. Journal of Clinical Medicine, 2020, 9, 2714.	2.4	12
228	Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study. Journal of Cystic Fibrosis, 2022, 21, 143-145.	0.7	12
229	Î²₂-Agonists for Asthma: The Pediatric Perspective. Clinical Reviews in Allergy and Immunology, 2006, 31, 209-218.	6.5	11
230	Assessment of body composition in pediatric patients with cystic fibrosis. Pediatric Pulmonology, 2008, 43, 1025-1032.	2.0	11
231	Cystic Fibrosis: a Review of Pulmonary and Nutritional Therapies. Advances in Pediatrics, 2008, 55, 99-121.	1.4	11
232	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. , 2012, 12, CD010004.		11
233	Lung arginase expression and activity is increased in cystic fibrosis mouse models. Journal of Applied Physiology, 2014, 117, 284-288.	2.5	11
234	Testing Two Different Doses of Tiotropium RespimatÂ® in Cystic Fibrosis: Phase 2 Randomized Trial Results. PLoS ONE, 2014, 9, e106195.	2.5	11

#	Article	IF	Citations
235	Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. Journal of Cystic Fibrosis, 2017, 16, 492-495.	0.7	11
236	Validation of multiple breath washout devices. Journal of Cystic Fibrosis, 2017, 16, e22-e23.	0.7	11
237	Growth of Pulmonary Arteriovenous Malformations in Pediatric Patients with Hereditary Hemorrhagic Telangiectasia. Journal of Pediatrics, 2019, 208, 279-281.	1.8	11
238	The utility of moment ratios and abbreviated endpoints of the multiple breath washout test in preschool children with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 649-653.	2.0	11
239	Lack of Association of Small-Colony-Variant Staphylococcus aureus Strains with Long-Term Use of Azithromycin in Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 2772-2773.	3.9	10
240	Effect of changes in tidal volume on multiple breath washout outcomes. PLoS ONE, 2019, 14, e0219309.	2.5	10
241	Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis. EBioMedicine, 2021, 73, 103660.	6.1	10
242	Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies. Journal of Cystic Fibrosis, 2022, 21, 282-292.	0.7	10
243	Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. Journal of Pediatrics, 2006, 149, 142.	1.8	9
244	Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. , 2009, , CD007481.		9
245	Update in Cystic Fibrosis 2011. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 933-936.	5.6	9
246	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. The Cochrane Library, 2016, 12, CD010004.	2.8	9
247	A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis. Genetics in Medicine, 2017, 19, 403-411.	2.4	9
248	Comparison of facemask and mouthpiece interfaces for multiple breath washout measurements. Journal of Cystic Fibrosis, 2018, 17, 511-517.	0.7	9
249	Blood biomarkers to predict short-term pulmonary exacerbation risk in children and adolescents with CF: A pilot study. Journal of Cystic Fibrosis, 2020, 19, 49-51.	0.7	9
250	Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Annals of Internal Medicine, 2021, 174, 1035-1036.	3.9	9
251	Surfactant Protein A in Cystic Fibrosis: Supratrimeric Structure and Pulmonary Outcome. PLoS ONE, 2012, 7, e51050.	2.5	9
252	Human adenosine 2B receptor: SNP discovery and evaluation of expression in patients with cystic fibrosis. Pharmacogenetics and Genomics, 2005, 15, 321-327.	1.5	8

#	Article	IF	Citations
253	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. , 2008, , CD006961.		8
254	Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. The Cochrane Library, 2012, 12, CD007481.	2.8	8
255	Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials, 2013, 36, 99-105.	1.8	8
256	Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. , 2014, , CD010004.		8
257	The prevalence of asthma in Canadian children of South Asian descent. Pediatric Pulmonology, 2014, 49, 43-48.	2.0	8
258	Changes in multiple breath washout measures after raised volume rapid thoracoabdominal compression maneuvers in infants. Pediatric Pulmonology, 2016, 51, 183-188.	2.0	8
259	Ventilation inhomogeneity in infants with recurrent wheezing. Thorax, 2018, 73, 936-941.	5.6	8
260	Paediatric reproducibility limits for the forced expiratory volume in 1 s. Thorax, 2020, 75, 891-896.	5.6	8
261	Dornase in non-CF. Pediatric Pulmonology, 2004, 37, 154-155.	2.0	7
262	Massive hemoptysis in an 11-year-old girl with isolated pulmonary arteritis. Pediatric Pulmonology, 2007, 42, 177-180.	2.0	7
263	Utility of MDCT MIP Postprocessing Reconstruction Images in Children With Hereditary Hemorrhagic Telangiectasia. Journal of Computer Assisted Tomography, 2016, 40, 375-379.	0.9	7
264	Long-term effect of CFTR modulator therapy on airway nitric oxide. European Respiratory Journal, 2020, 55, 1901113.	6.7	7
265	Persistent ventilation inhomogeneity after an acute exacerbation in preschool children with recurrent wheezing. Pediatric Allergy and Immunology, 2020, 31, 608-615.	2.6	7
266	A multimodal approach to detect and monitor early lung disease in cystic fibrosis. Expert Review of Respiratory Medicine, 2021, 15, 761-772.	2.5	7
267	Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease. Npj Genomic Medicine, 2022, 7, 28.	3.8	7
268	Newborn screening for cystic fibrosis. Canadian Family Physician, 2021, 67, e144-e152.	0.4	7
269	Airway nitric oxide in Duchenne muscular dystrophy. Journal of Pediatrics, 2002, 141, 132-134.	1.8	6
270	Amiloride. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1191-1192.	5.6	6

#	Article	IF	Citations
271	Pooled analysis of tiotropium RespimatÂ® pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology and Therapeutics, 2014, 29, 217-223.	2.6	6
272	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. , 2015, , CD006961.		6
273	Reference equations for the interpretation of forced expiratory and plethysmographic measurements in infants. Pediatric Pulmonology, 2018, 53, 907-916.	2.0	6
274	Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. The Cochrane Library, 2020, 6, CD009528.	2.8	6
275	Aerosolized lancovutide in adolescents (â‰¥12 years) and adults with cystic fibrosis â€“ a randomized trial. Journal of Cystic Fibrosis, 2021, 20, 61-67.	0.7	6
276	Unsupervised phenotypic clustering for determining clinical status in children with cystic fibrosis. European Respiratory Journal, 2021, 58, 2002881.	6.7	6
277	CFTR-function and ventilation inhomogeneity in individuals with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 641-647.	0.7	6
278	Evaluation of clinically relevant changes in the lung clearance index in children with cystic fibrosis and healthy controls. Thorax, 2023, 78, 362-367.	5.6	6
279	The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2022, 21, 759-765.	0.7	6
280	Multitracer Stable Isotope Quantification of Arginase and Nitric Oxide Synthase Activity in a Mouse Model of Pseudomonas Lung Infection. Mediators of Inflammation, 2014, 2014, 1-7.	3.0	5
281	Commentaries on Viewpoint: Using the same cut-off for sulfur hexafluoride and nitrogen multiple-breath washout may not be appropriate. Journal of Applied Physiology, 2015, 119, 1513-1514.	2.5	5
282	Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 1221-1228.	2.5	5
283	Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis. Frontiers in Pharmacology, 2020, 11, 576293.	3.5	5
284	Multiple breath washout in bronchiectasis clinical trials: is it feasible?. ERJ Open Research, 2020, 6, 00363-2019.	2.6	5
285	Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1018-1025.	0.7	5
286	The Effect of Rapid Thoracoabdominal Compressions on Intracranial Pressure in Newborn Lambs. Pediatric Research, 1995, 38, 664-667.	2.3	4
287	Gender-specific disease modification by NOS3. British Journal of Haematology, 2004, 126, 160-160.	2.5	4
288	Early interventions in CF. Pediatric Pulmonology, 2004, 37, 88-90.	2.0	4

#	Article	IF	Citations
289	Pulmonary artery hypertension: an underrated disease manifestation in cystic fibrosis?. Lancet Respiratory Medicine,the, 2016, 4, 596-598.	10.7	4
290	Elucidating progression of early cystic fibrosis lung disease. European Respiratory Journal, 2017, 50, 1701916.	6.7	4
291	Echocardiography Grading for Pulmonary Arteriovenous Malformation Screening in Children with Hereditary Hemorrhagic Telangiectasia. Journal of Pediatrics, 2018, 195, 288-291.e1.	1.8	4
292	Evaluation of a multiple breath nitrogen washout system in children. Pediatric Pulmonology, 2020, 55, 2108-2114.	2.0	4
293	Changes in the parent cystic fibrosis questionnaire-revised (CFQ-R) with respiratory symptoms in preschool children with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 492-498.	0.7	4
294	Lung compartment analysis assessed from N₂ multipleâ€breath washout in children with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 1671-1680.	2.0	4
295	Primary care providersâ€™ role in newborn screening result notification for cystic fibrosis. Canadian Family Physician, 2021, 67, 439-448.	0.4	4
296	Pharmacokinetics of inhaled colistin in patients with cystic fibrosis: authors' response. Journal of Antimicrobial Chemotherapy, 2006, 58, 223-223.	3.0	3
297	Acute antibiotic use in cystic fibrosis clinical trials: does it affect our assessment of clinical efficacy?. Lancet Respiratory Medicine,the, 2013, 1, 98-99.	10.7	3
298	Clinimetric Properties of the Lung Clearance Index in Adults and Children With Cystic Fibrosis. Chest, 2016, 150, 1412-1413.	0.8	3
299	The effects of 100% oxygen on breathing pattern are not limited to young children. European Respiratory Journal, 2018, 51, 1702055.	6.7	3
300	Retracing changes in cystic fibrosis understanding and management over the past twenty years. Journal of Cystic Fibrosis, 2022, 21, 3-9.	0.7	3
301	Re: Impact of spiroware re-analysis method on multiple-breath washout outcomes in children with cystic fibrosis; M.A. Oestreich, F. Wyler, P. Latzin etÂal.. Journal of Cystic Fibrosis, 2022, 21, e210-e211.	0.7	3
302	Comparative analysis of respiratory symptom scores to detect acute respiratory events in children with cystic fibrosis. Journal of Cystic Fibrosis, 2023, 22, 296-305.	0.7	3
303	Aerosol therapy in cystic fibrosis: Weighing the evidence. Pediatric Pulmonology, 2008, 43, S3-S4.	2.0	2
304	Positional oximetry to screen for pulmonary arteriovenous malformations in HHT: TableÂ1. Thorax, 2014, 69, 1045-1045.	5.6	2
305	Infant spirometry as a predictor of lung function at early childhood in cystic fibrosis patients. Journal of Cystic Fibrosis, 2020, 20, 937-940.	0.7	2
306	Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis. European Respiratory Journal, 2020, 56, 2000175.	6.7	2

#	Article	IF	Citations
307	The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. Journal of Personalized Medicine, 2021, 11, 382.	2.5	2
308	Newly developed multiple-breath washout reference equations from the CHILD Cohort Study: implications of poorly fitting equations. ERJ Open Research, 2021, 7, 00301-2020.	2.6	2
309	Aquagenic wrinkling of the palms in cystic fibrosis patients treated with ivacaftor. Journal of Cystic Fibrosis, 2022, 21, e102-e105.	0.7	2
310	Neurovascular Manifestations in Pediatric Patients With Hereditary Haemorrhagic Telangiectasia. Pediatric Neurology, 2022, 129, 24-30.	2.1	2
311	Nonâ€invasive MR imaging techniques for measuring femoral arterial flow in a pediatric and adolescent cohort. Physiological Reports, 2022, 10, .	1.7	2
312	MRI: the next frontier for cystic fibrosis clinicians?. Expert Review of Respiratory Medicine, 2008, 2, 179-182.	2.5	1
313	Asymmetric Dimethylarginine (ADMA) In Cystic Fibrosis Lung Disease. , 2010, , .		1
314	Response to letter. Pediatric Pulmonology, 2015, 50, 105-105.	2.0	1
315	Reply to Verbanck and Vanderhelst: The Respective Roles of Lung Clearance Index and Magnetic Resonance Imaging in the Clinical Management of Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 411-412.	5.6	1
316	Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. The Cochrane Library, 2021, 2021, CD006961.	2.8	1
317	The remaining barriers to normalcy in CF: Advances in assessment of CF lung disease. Pediatric Pulmonology, 2021, 56, S90-S96.	2.0	1
318	Bronchodilator responsiveness in cystic fibrosis children treated for pulmonary exacerbations. Pediatric Pulmonology, 2021, 56, 2036-2042.	2.0	1
319	Utility of modified Rankin Scale for brain vascular malformations in hereditary hemorrhagic telangiectasia. Orphanet Journal of Rare Diseases, 2021, 16, 390.	2.7	1
320	Tracking pulmonary exacerbations in preschool children using the lung clearance index. , 2016, , .		1
321	New reference values for N₂multiple breath washout outcomes in pre-school and school-aged children. , 2016, , .		1
322	Potential of Denufosol as an Early Intervention Therapy for CF Lung Disease. FASEB Journal, 2010, 24, 31.9.	0.5	1
323	ATS Core Curriculum 2014: Part IV. Pediatric Pulmonary Medicine.. Annals of the American Thoracic Society, 2014, 11, 1633-1639.	3.2	1
324	Newborn screening for cystic fibrosis: Role of primary care providers in caring for infants with positive screening results. Canadian Family Physician, 2021, 67, e144-e152.	0.4	1

#	Article	IF	Citations
325	Lower Airway Nitrogen Oxide Levels in Children with Primary Ciliary Dyskinesia Is Linked to Neutrophilic Inflammation. Journal of Pediatrics, 2022, 244, 230-233.	1.8	1
326	Interleukin-1 beta is a potential mediator of airway nitric oxide deficiency in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 623-625.	0.7	1
327	How Best to Capture Early Cystic Fibrosis Lung Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 283-284.	5.6	1
328	Bronchoalveolar lavage: Don't forget the size of the bronchoscope. Pediatric Pulmonology, 1996, 22, 330-331.	2.0	0
329	Editorial: Leukocyte trafficking and matrix metalloproteinase-8 in obliterative bronchiolitis. Journal of Leukocyte Biology, 2010, 87, 23-24.	3.3	0
330	Tiotropium bromide for cystic fibrosis. Expert Opinion on Orphan Drugs, 2015, 3, 957-966.	0.8	0
331	Author's Response: Re: Stratifying Cystic Fibrosis Risk for Newborn Screen Infants With Equivocal Sweat Chloride Levels. Pediatrics, 2015, 136, e1490-e1491.	2.1	0
332	Constrictive Bronchiolitis: A Distinct Phenotype of Cystic Fibrosis Lung Disease?. Annals of the American Thoracic Society, 2016, 13, 2111-2112.	3.2	0
333	New insights into disease progression for the CFTR modulator-treated cystic fibrosis patient. Journal of Cystic Fibrosis, 2016, 15, e21.	0.7	0
334	Chronic Hypoxemia in a 2-Year-Old Boy. Annals of the American Thoracic Society, 2017, 14, 1348-1352.	3.2	0
335	Another Brick in the Wall: Lung Clearance Index and Lower Airways Pathology in Preschool Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 1389-1390.	3.2	0
336	Does the multiple-breath washout test need to be measured before spirometry?. ERJ Open Research, 2019, 5, 00230-2018.	2.6	0
337	Apples to apples? Comparative analyses of national CF registries. Thorax, 2022, 77, 112-113.	5.6	0
338	The Trp64Arg polymorphism in the Î² ₃ â€adrenergic receptor gene is not associated with pulmonary function in cystic fibrosis. FASEB Journal, 2006, 20, .	0.5	0
339	End-points and biomarkers for clinical trials in cystic fibrosis. , 2014, , 104-115.		0
340	Basic science: What will it deliver? Non-gene therapy treatments. , 2015, , 620-624.		0
341	Cystic Fibrosis: Treatment. , 2020, , 453-466.		0
342	Primary care providers' role in newborn screening result notification for cystic fibrosis. Canadian Family Physician, 2021, 67, 439-448.	0.4	0

#	Article	IF	Citations
343	COMBATing airway inflammation in infants with cystic fibrosis. Lancet Respiratory Medicine,the, 2022, , .	10.7	0